Advanced in Chronic Graft Versus Host Disease (cGvHD)

Liane E. Daudt

Porto Alegre, RS, BR 
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Porto Alegre, RS, BR 
OverviewLocationsClinical Research

Overview

Liane Daudt practices in Porto Alegre, Brazil. Ms. Daudt is rated as an Advanced expert by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). Her top areas of expertise are Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Chronic Graft Versus Host Disease (cGvHD).

Gender
Female

Locations

Porto Alegre, RS, Brazil
Other Locations
Rio Grande, RS, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

62 Total Publications

Serum hepcidin as a biomarker of treatment response in Gaucher disease.
Serum hepcidin as a biomarker of treatment response in Gaucher disease.
Journal: Molecular genetics and metabolism reports
Published: June 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Daudt's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile